Search | OpenScholar

Search results

817 results found

Levodopa-induced dyskinesia in Parkinson’s disease: epidemiology, etiology, and treatment.

Publication: Journal Article

Zesiewicz, TA, CL Ward, RA Hauser, JL Salemi, S Siraj, MC Wilson, and KL Sullivan. 2007. “Levodopa-Induced Dyskinesia in Parkinson’s Disease: Epidemiology, Etiology, and Treatment.”. Curr Neurol Neurosci Rep.

Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson’s disease. Movement Disorders 2005;20:1205-1209.

Publication: Journal Article

Zesiewicz, TA, KL Sullivan, JL Maldonado, and RA Hauser. 2005. “Open-Label Pilot Study of Levetiracetam (Keppra) for the Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease. Movement Disorders 2005;20:1205-1209.”. Movement Disorders.

Levodopa response in early Parkinson’s disease

Publication: Journal Article

Hauser, RA, P Auinger, and D Oakes. 2009. “Levodopa Response in Early Parkinson’s Disease”. Mov Disord.

Delayed thalamic intracranial hemorrhage in an essential tremor patient following deep brain stimulation

Publication: Journal Article

Zesiewicz, TA, KL Sullivan, M Hoffman, LM Benes, DA Smith, CL Ward, and RA Hauser. 2008. “Delayed Thalamic Intracranial Hemorrhage in an Essential Tremor Patient Following Deep Brain Stimulation”. Eur Neurol.

Ropinirole for Restless Legs Syndrome: A Placebo-Controlled Crossover Trial. Neurology 2004;62:1405-1407.

Publication: Journal Article

Adler, CH, RA Hauser, K Sethi, JN Caviness, L Marlor, M Anderson, and JG Hentz. 2004. “Ropinirole for Restless Legs Syndrome: A Placebo-Controlled Crossover Trial. Neurology 2004;62:1405-1407.”. Neurology.

Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorder. Hum Genet 2003;113:154-161.

Publication: Journal Article

Crawford, FC, G Ait-Ghezala, M Morris, MJ Sutcliffe, RA Hauser, AA Silver, and MJ Mullan. 2003. “Translocation Breakpoint in Two Unrelated Tourette Syndrome Cases, Within a Region Previously Linked to the Disorder. Hum Genet 2003;113:154-161.”. Hum Genet.

Clozapine withdrawal symptoms in a Parkinson’s disease patient. Movement Disorders 2002;17:1365-1367.

Publication: Journal Article

Zesiewicz, TA, S Borra, and RA Hauser. 2002. “Clozapine Withdrawal Symptoms in a Parkinson’s Disease Patient. Movement Disorders 2002;17:1365-1367.”. Movement Disorders.

Glaucoma drainage devices: state of the art

Publication: Journal Article

Ayyala, Ramesh S, Jessica Laursen Duarte, and . 2006. “Glaucoma Drainage Devices: State of the Art”. Expert Rev. Med. Devices 3 (4): 509-21.

Manganese and liver disease. Movement Disorders 1996;11:589.

Publication: Journal Article

Hauser, RA, and TA Zesiewicz. 1996. “Manganese and Liver Disease. Movement Disorders 1996;11:589.”. Movement Disorders.

Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. NEJM 1995;332:1118-24.

Publication: Journal Article

Kordower, JH, TB Freeman, BJ Snow, FJG Vingerhoets, EJ Mufson, PR Sanberg, RA Hauser, et al. 1995. “Neuropathological Evidence of Graft Survival and Striatal Reinnervation After the Transplantation of Fetal Mesencephalic Tissue in a Patient With Parkinson’s Disease. NEJM 1995;332:1118-24.”. NEJM.